The Irish company made its interest for Auxilium public, but the takeover target is not ready to break its previous merger agreement with Canadian drugmaker QLT.

Valeant attributes 14% organic growth in U.S. sales to Bausch + Lomb acquisition, disputing Allergan assertion that the deal has not borne fruit. Vertex sees evidence of sustained benefit for CF patients in Kalydeco long-term usage study. Other updates from the second quarter earnings calls, in brief.

Endo expanded its generics business by purchasing Dava, EMD Serono partnered with Mersana on antibody-drug conjugates and Ligand in-licensed a cancer and autoimmune disease candidate from TG Therapeutics. It was all part of a hectic deal-making week coinciding with the annual BIO conference in San Diego.

The acquisitive specialty pharma will buy privately-held generics firm Dava Pharmaceuticals for $575 million in cash and potentially another $25 million based on the achievement of certain sales milestones.